Found: 18
Select item for more details and to access through your institution.
GLOBAL COLLABORATION TO PROVIDE DRUG INTERACTION GUIDANCE FOR NIRMATRELVIR/RITONAVIR.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 202
- By:
- Publication type:
- Article
Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 6, p. 1191, doi. 10.1002/cpt.2646
- By:
- Publication type:
- Article
Are UK pharmacists ready for consultant-level practice? A cross-sectional survey of self-assessed development needs.
- Published in:
- International Journal of Pharmacy Practice, 2022, v. 30, n. 6, p. 559, doi. 10.1093/ijpp/riac070
- By:
- Publication type:
- Article
Safe co‐administration of direct‐acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study.
- Published in:
- Journal of Viral Hepatitis, 2022, v. 29, n. 12, p. 1073, doi. 10.1111/jvh.13750
- By:
- Publication type:
- Article
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.
- Published in:
- Infectious Diseases & Therapy, 2021, v. 10, n. 4, p. 2203, doi. 10.1007/s40121-021-00455-1
- By:
- Publication type:
- Article
Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
- Published in:
- Drugs in R&D, 2021, v. 21, n. 1, p. 9, doi. 10.1007/s40268-020-00333-0
- By:
- Publication type:
- Article
COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions.
- Published in:
- British Journal of Clinical Pharmacology, 2021, v. 87, n. 1, p. 212, doi. 10.1111/bcp.14358
- By:
- Publication type:
- Article
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 4, p. 371, doi. 10.1111/jvh.13239
- By:
- Publication type:
- Article
Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy.
- Published in:
- Open Forum Infectious Diseases, 2020, v. 7, n. 2, p. N.PAG, doi. 10.1093/ofid/ofaa040
- By:
- Publication type:
- Article
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 8, p. 951, doi. 10.1111/jvh.13110
- By:
- Publication type:
- Article
Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries
- Published in:
- Journal of Viral Hepatitis, 2019, v. 26, n. 6, p. 685, doi. 10.1111/jvh.13080
- By:
- Publication type:
- Article
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.
- Published in:
- British Journal of Clinical Pharmacology, 2018, v. 84, n. 5, p. 961, doi. 10.1111/bcp.13519
- By:
- Publication type:
- Article
Drug-Drug Interactions With Novel All Oral Interferon- Free Antiviral Agents in a Large Real-World Cohort.
- Published in:
- Clinical Infectious Diseases, 2016, v. 62, n. 5, p. 561, doi. 10.1093/cid/civ973
- By:
- Publication type:
- Article